Volltext verfügbar nach Anmeldung bzw. im Campus-Netz.
ALX Oncology’s ALX148 Receives Two Fast Track Designations from FDA for the Treatment of Patients with Head and Neck Squamous Cell Carcinoma and Patients with Gastric or Gastroesophageal Junction Adenocarcinoma
In: Business Wire (English), 2020-02-18
Online
Zeitungsartikel
Zugriff:
ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced that the U.S. Food and Drug Administration (FDA) has granted two Fast Track designations for its lead candidate, ALX148, for the first-line treatment of patients with head and neck squamous cell carcinoma (HNSCC), and for the second-line treatment of patients with HER2-positive gastric or gastroesophageal junction (gastric/GEJ) carcinoma. Data supporting these Fast Track designations were based on an open-label, multicenter Phase 1 clinical trial of ALX148 in combination with pembrolizumab or trastuzumab. [ABSTRACT FROM PUBLISHER]
Titel: |
ALX Oncology’s ALX148 Receives Two Fast Track Designations from FDA for the Treatment of Patients with Head and Neck Squamous Cell Carcinoma and Patients with Gastric or Gastroesophageal Junction Adenocarcinoma
|
---|---|
Autor/in / Beteiligte Person: | Oncology, ALX |
Zeitschrift: | Business Wire (English), 2020-02-18 |
Veröffentlichung: | 2020 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|